An Epidemiology Study of Treatment Resistant Depression in the United States (US)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03109002|
Recruitment Status : Completed
First Posted : April 11, 2017
Last Update Posted : June 8, 2017
|Condition or disease|
|Depressive Disorder, Treatment-Resistant|
|Study Type :||Observational|
|Actual Enrollment :||200000 participants|
|Official Title:||Epidemiology of Treatment Resistant Depression in the US: Analysis of Health Services Databases|
|Actual Study Start Date :||January 15, 2017|
|Actual Primary Completion Date :||May 18, 2017|
|Actual Study Completion Date :||May 18, 2017|
Cohort: Pharmacologically Treated Depression (PTD) Cases
This study is based on anonymized health services data, study population include US residents with medical insurance between 1 Jan, 2010 and 31 Dec, 2014 as described by the Truven MarketScan Medicaid (MDCD), Truven MarketScan Medicare Supplemental (MCDR), and Truven MarketScan Commercial Claims and Encounters (CCAE) databases. Within each database, pharmacologically treated depression (PTD) cases incident during 2011 will be followed for up to 4 years to ascertain their TRD status and 1-year incidence rates for PTD and TRD. Participants will not receive any intervention as a part of this study. To assure they are incident rather than prevalent cases, study participants are required to have 1 year without a dispensing of an antidepressant medication before they can join the cohort.
- Incidence Rate of Treatment Resistant Depression [ Time Frame: Up to 4 years ]TRD will be defined as the failure of two medications, as marked by their replacement or supplementation with other medications using three alternative definitions. In one the time for a medication regimen to fail is limited to less than or equal to (<=) 3 months and in the second the time for a medication regimen to fail is limited to <= 6 months, both corresponding to the medication never providing adequate relief. In the third, the time for a medication regimen to fail will be limited to <= 2 years, corresponding to the medication not providing permanent or very long lasting relief.
- Treatment Resistant Depression as a Proportion of Pharmacologically Treated Depression [ Time Frame: Up to 4 years ]An episode of PTD begins when a member of the study cohort receives a dispensing of an antidepressant (AD) medication and receives a diagnosis of depression between 180 days before that dispensing and 30 days after that dispensing.
- Incidence Rate of Treatment Resistant Depression by Age Group and Sex [ Time Frame: Up to 4 years ]TRD incidence will be stratified by age group and sex under each of the three definitions of failure of a medication regimen.
- Incidence Rate of TRD as Separate Estimates for the Medicaid Population, the Medicare Population, and the Privately Insured Population [ Time Frame: Up to 4 years ]TRD incidence will be stratified by data population (database): Medicaid, Medicare, Privately insured.
- Incidence on TRD Based on Sensitivity Analysis [ Time Frame: Up to 4 years ]Sensitivity analyses are intended to clarify how the results of the present study will compare to the results of other studies that may define as The maximum time for failure of a regimen is changed to: 60, 120, 150, or 365 days, or is not limited; the requirement that a regimen include greater than or equal to (>=) 28 days' supply of the antidepressant medication and antipsychotic medication (if present) is changed to >= 42 days and 14 days supply; participants who get an excluded diagnosis are retroactively excluded from the study cohort; or the definition of an incident case adds a requirement for no depression diagnosis in the prior year.
- Number of Participants With Selected Markers for Severity of Depression [ Time Frame: Up to 4 years ]The following markers of severity will be tabulated during the PTD episodes and stratified according to whether the participant develops or does not develop TRD during the study period: Electro-convulsive therapy, hospitalization with a diagnosis of depression, receiving a diagnosis of suicidal thoughts, receiving a diagnosis of self-harm, emergency department visit with a diagnosis of injury, emergency department visit with a diagnosis of poisoning.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03109002
|Study Director:||Janssen Research & Development, LLC Clinical Trial||Janssen Research & Development, LLC|